Press Release Archive

Innovation September 21, 2021

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

Additional data show a booster increases protection

94 percent protection in the U.S. with booster given at two months

Four-fold increase in antibodies when given at two months

12-fold increase in antibodies when booster given at six months

Innovation September 19, 2021

New Data on RYBREVANT^® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy

New Data on RYBREVANT^® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy

CHRYSALIS-2 findings presented at ESMO Annual Congress 2021 suggest that RYBREVANT® and lazertinib combination has encouraging anti-tumor activity in this population that has exhausted standard-of-care treatments

Innovation September 19, 2021

RYBREVANT^®(amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib

RYBREVANT^®(amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib

New analysis from CHRYSALIS study presented at the ESMO Annual Congress 2021 supports simultaneously targeting the extracellular and catalytic domains of EGFR

Innovation September 17, 2021

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA^® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA^® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor

Oral presentation at ESMO Annual Congress 2021 – featured in a late-breaking abstract – reports efficacy and safety of BALVERSA^®in combination with a PD-1 inhibitor in bladder cancer

Financial September 16, 2021

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Innovation September 13, 2021

Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases

Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases

Data show the vaccine regimen induced neutralizing antibody responses in nearly all participating adults and children 21 days after the second dose

Adults receiving booster shots two years after initial vaccination regimen showed strong immune responses

The data support the potential prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect adults and children

September 11, 2021

ERLEADA^®(apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates

ERLEADA^®(apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates

Post-hoc analysis shows that ERLEADA® provides rapid, deep and durable PSA declines in advanced prostate cancer, with depth and speed of response correlating to improved overall survival

Real-world data demonstrate that, across racial groups, patients prescribed ERLEADA® for non-metastatic castration-resistant prostate cancer stay on therapy

Innovation September 08, 2021

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress

Data for approved and investigational treatments to be presented in bladder cancer, lung cancer and prostate cancer

Investigational RYBREVANT^®(amivantamab-vmjw) and lazertinib combination therapy in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) to be featured in oral presentations

Innovation September 01, 2021

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™
(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™
(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia

INVEGA HAFYERA™ offers patients the fewest doses per year for a life less defined by schizophrenia medication

Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months

Approval is backed by nearly two decades of proven efficacy and safety of Janssen’s long-acting injectable portfolio of schizophrenia medicines

Our Company August 31, 2021

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021

Compelled to advance innovation for patients and the urology community,

oral presentations highlight real-world effectiveness of and patient adherence to ERLEADA^® (apalutamide), plus PSA response from Phase 3 TITAN and SPARTAN studies in patients with advanced prostate cancer

Internet Explorer is no longer supported by this website.

Topic

Date

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021